[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy]

Zhonghua Jie He He Hu Xi Za Zhi. 1998 Nov;21(11):645-7.
[Article in Chinese]


Objective: To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China.

Method: Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation.

Result: The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively.

Conclusion: Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Isoniazid / administration & dosage*
  • Male
  • Middle Aged
  • Pyrazinamide / administration & dosage*
  • Rifampin / administration & dosage*
  • Tuberculosis, Pulmonary / drug therapy*


  • Antitubercular Agents
  • Pyrazinamide
  • Isoniazid
  • Rifampin